Assessing the effectiveness of teclistamab for multiple myeloma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the clinical efficacy and safety of teclistamab (Tecvayli®) in patients with relapsed or refractory multiple myeloma who have undergone at least three prior treatments. Participants will be monitored in a real-life setting in Belgium for a duration of up to 24 months, with monthly follow-ups for the first six months and subsequent assessments every three months. The study will track patient responses and any adverse effects associated with the treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 years or older
* Written informed consent
* Has a diagnosis of relapsed and refractory multiple myeloma
* Has already received at least three previous treatments
* Is refractory to at least 1 proteasome inhibitor, at least 1 immunomodulatory agent, and an anti-CD38 monoclonal antibody
* Evidence of disease progression on the last line of therapy, based on determination of response by the IMWG response criteria
* Anticipated to start treatment with teclistamab or talquetamab per routine clinical care or has started with teclistamab treatment ≤28 days before intended screening visit

Exclusion Criteria:

* Has started teclistamab or talquetamab treatment \>28 days before intended screening visit.
* Inability or unwillingness to comply with the study protocol, including scheduled visits, treatment plans, or follow-up requirements.

Where it's running

• Universitair Ziekenhuis Antwerpen (UZA)
  Edegem, Antwerpen, Belgium Recruiting
• Grand Hôpital de Charleroi
  Charleroi, Henegouwen, Belgium Recruiting
• EpiCURA
  Hornu, Henegouwen, Belgium Recruiting
• CHU Ambroise Paré
  Mons, Henegouwen, Belgium Recruiting
• Jessa Ziekenhuis
  Hasselt, Limburg, Belgium Recruiting
• CHR Citadelle
  Liège, Liège, Belgium Recruiting

Study contacts

• Principal investigator: Michel Delforge, MD, PhD — UZ Leuven Gasthuisberg
• Study coordinator: Michel Delforge, MD, PhD
• Email: michel.delforge@uzleuven.be
• Phone: +32 16 34 68 80

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using bispecific T-cell redirectors for first-line treatment in transplant-eligible multiple myeloma patients

  This study is testing if a new combination of treatments can help newly diagnosed multiple myeloma patients who are eligible for a stem cell transplant feel better and improve their outcomes.

  Recruiting Phase 2 North Estonia Medical Centre · Copenhagen and 6 other locations · NCT06505369

• Combination treatment for high-risk smoldering multiple myeloma

  This study is testing two different combination treatments to see which one helps people with high-risk smoldering multiple myeloma delay their disease from getting worse.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT06100237

• Outpatient treatment for multiple myeloma using teclistamab or talquetamab

  This study is testing if two new treatments, teclistamab and talquetamab, can safely help adults with relapsed or hard-to-treat multiple myeloma when given as outpatient care.

  Recruiting at 16 sites Phase 2 SCRI Development Innovations, LLC · Tucson, Arizona and 16 other locations · NCT05972135

• Combination treatment for newly diagnosed multiple myeloma patients

  This study is testing a new combination treatment for people with newly diagnosed multiple myeloma to see if it can be a safer and more effective alternative to traditional high-dose therapy and stem cell transplants.

  Recruiting at 11 sites Phase 2 University of Heidelberg Medical Center · Berlin and 10 other locations · NCT05695508

• Combining teclistamab and talquetamab with daratumumab and lenalidomide for newly diagnosed multiple myeloma

  This study is testing two new treatment combinations for people with newly diagnosed multiple myeloma to see if they work better than the standard treatment.

  Recruiting at 66 sites Phase 3 Janssen Research & Development, LLC · Gilbert, Arizona and 269 other locations · NCT05552222

• Infliximab to Help Prevent CRS During Teclistamab or Talquetamab Therapy in Relapsed/Refractory Myeloma

  This phase 2 trial tests whether infliximab can prevent cytokine release syndrome in patients with relapsed or refractory multiple myeloma who are being treated with teclistamab or talquetamab.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07657312

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.